FTXH
First Trust Nasdaq Pharmaceuticals ETF
Price Chart
Latest Quote
$43.12
+0.31 (+0.72%)
Current Price
| Previous Close | $42.81 |
| Open | $42.71 |
| Day High | $43.12 |
| Day Low | $42.61 |
| Volume | 27,130 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.70% |
| Net Assets | $1.06B |
| Expense Ratio | 0.60% |
| Category | Health |
| Fund Family | First Trust |
| Net Asset Value | $42.76 |
| Premium/Discount | 0.84% |
| Quarterly Dividend Yield | 0.70% |
| P/E Ratio | 27.05 |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $41.60 |
| SMA50 | $41.55 |
| SMA200 | $36.97 |
| RSI | 69.17 |
| ATR | 0.7314 |
| Rel Volume | 0.21 |
Performance History
| Week | +0.97% |
| Month | +3.02% |
| Quarter | +9.25% |
| 6 Months | +29.06% |
| YTD | +30.75% |
| Year | +47.48% |
| 3 Years | +79.58% |
| 5 Years | +78.72% |
| 10 Years | +154.71% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $43.12 | 27,100 |
| 2026-10-26 | $42.81 | 57,600 |
| 2026-10-23 | $42.67 | 83,500 |
| 2026-10-22 | $43.20 | 132,600 |
| 2026-10-21 | $42.75 | 52,100 |
| 2026-10-20 | $42.71 | 180,200 |
| 2026-10-19 | $41.59 | 42,200 |
| 2026-10-16 | $41.66 | 24,800 |
| 2026-10-15 | $41.97 | 60,600 |
| 2026-10-14 | $41.29 | 32,700 |
| 2026-10-13 | $40.43 | 28,500 |
| 2026-10-12 | $41.25 | 25,400 |
| 2026-10-09 | $41.27 | 1,263,400 |
| 2026-10-08 | $40.45 | 33,700 |
| 2026-10-07 | $40.67 | 84,800 |
| 2026-10-06 | $40.45 | 108,100 |
| 2026-10-05 | $40.76 | 139,500 |
| 2026-10-02 | $40.73 | 53,700 |
| 2026-10-01 | $40.82 | 103,600 |
| 2026-09-30 | $41.47 | 37,300 |
| 2026-09-29 | $41.77 | 37,200 |
| 2026-09-28 | $41.86 | 76,500 |
About First Trust Nasdaq Pharmaceuticals ETF
The fund will normally invest at least 80% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.
đ° Latest News
No news articles available at the moment. Check back later for updates on FTXH.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.